Molecular and clinical determinants of response and resistance to rucaparib for recurrent ovarian cancer treatment in ARIEL2 (Parts 1 and 2)

The identification of biomarkers of response to PARP inhibitors can enable selection of appropriate ovarian cancer patients for treatment. In this study, the authors report clinical results and exploratory biomarker analyses from the ARIEL2 phase 2 clinical trial on the safety and efficacy of the PA...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Elizabeth M. Swisher, Tanya T. Kwan, Amit M. Oza, Anna V. Tinker, Isabelle Ray-Coquard, Ana Oaknin, Robert L. Coleman, Carol Aghajanian, Gottfried E. Konecny, David M. O’Malley, Alexandra Leary, Diane Provencher, Stephen Welch, Lee-may Chen, Andrea E. Wahner Hendrickson, Ling Ma, Prafull Ghatage, Rebecca S. Kristeleit, Oliver Dorigo, Ashan Musafer, Scott H. Kaufmann, Julia A. Elvin, Douglas I. Lin, Setsuko K. Chambers, Erin Dominy, Lan-Thanh Vo, Sandra Goble, Lara Maloney, Heidi Giordano, Thomas Harding, Alexander Dobrovic, Clare L. Scott, Kevin K. Lin, Iain A. McNeish
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Science Q
Acceso en línea:	https://doaj.org/article/4c0bb318d2464bacb5fcd01f6ceefda3
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:4c0bb318d2464bacb5fcd01f6ceefda3
record_format	dspace
spelling	oai:doaj.org-article:4c0bb318d2464bacb5fcd01f6ceefda32021-12-02T14:29:13ZMolecular and clinical determinants of response and resistance to rucaparib for recurrent ovarian cancer treatment in ARIEL2 (Parts 1 and 2)10.1038/s41467-021-22582-62041-1723https://doaj.org/article/4c0bb318d2464bacb5fcd01f6ceefda32021-05-01T00:00:00Zhttps://doi.org/10.1038/s41467-021-22582-6https://doaj.org/toc/2041-1723The identification of biomarkers of response to PARP inhibitors can enable selection of appropriate ovarian cancer patients for treatment. In this study, the authors report clinical results and exploratory biomarker analyses from the ARIEL2 phase 2 clinical trial on the safety and efficacy of the PARP inhibitor rucaparib in patients with recurrent ovarian cancersElizabeth M. SwisherTanya T. KwanAmit M. OzaAnna V. TinkerIsabelle Ray-CoquardAna OakninRobert L. ColemanCarol AghajanianGottfried E. KonecnyDavid M. O’MalleyAlexandra LearyDiane ProvencherStephen WelchLee-may ChenAndrea E. Wahner HendricksonLing MaPrafull GhatageRebecca S. KristeleitOliver DorigoAshan MusaferScott H. KaufmannJulia A. ElvinDouglas I. LinSetsuko K. ChambersErin DominyLan-Thanh VoSandra GobleLara MaloneyHeidi GiordanoThomas HardingAlexander DobrovicClare L. ScottKevin K. LinIain A. McNeishNature PortfolioarticleScienceQENNature Communications, Vol 12, Iss 1, Pp 1-13 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Science Q
spellingShingle	Science Q Elizabeth M. Swisher Tanya T. Kwan Amit M. Oza Anna V. Tinker Isabelle Ray-Coquard Ana Oaknin Robert L. Coleman Carol Aghajanian Gottfried E. Konecny David M. O’Malley Alexandra Leary Diane Provencher Stephen Welch Lee-may Chen Andrea E. Wahner Hendrickson Ling Ma Prafull Ghatage Rebecca S. Kristeleit Oliver Dorigo Ashan Musafer Scott H. Kaufmann Julia A. Elvin Douglas I. Lin Setsuko K. Chambers Erin Dominy Lan-Thanh Vo Sandra Goble Lara Maloney Heidi Giordano Thomas Harding Alexander Dobrovic Clare L. Scott Kevin K. Lin Iain A. McNeish Molecular and clinical determinants of response and resistance to rucaparib for recurrent ovarian cancer treatment in ARIEL2 (Parts 1 and 2)
description	The identification of biomarkers of response to PARP inhibitors can enable selection of appropriate ovarian cancer patients for treatment. In this study, the authors report clinical results and exploratory biomarker analyses from the ARIEL2 phase 2 clinical trial on the safety and efficacy of the PARP inhibitor rucaparib in patients with recurrent ovarian cancers
format	article
author	Elizabeth M. Swisher Tanya T. Kwan Amit M. Oza Anna V. Tinker Isabelle Ray-Coquard Ana Oaknin Robert L. Coleman Carol Aghajanian Gottfried E. Konecny David M. O’Malley Alexandra Leary Diane Provencher Stephen Welch Lee-may Chen Andrea E. Wahner Hendrickson Ling Ma Prafull Ghatage Rebecca S. Kristeleit Oliver Dorigo Ashan Musafer Scott H. Kaufmann Julia A. Elvin Douglas I. Lin Setsuko K. Chambers Erin Dominy Lan-Thanh Vo Sandra Goble Lara Maloney Heidi Giordano Thomas Harding Alexander Dobrovic Clare L. Scott Kevin K. Lin Iain A. McNeish
author_facet	Elizabeth M. Swisher Tanya T. Kwan Amit M. Oza Anna V. Tinker Isabelle Ray-Coquard Ana Oaknin Robert L. Coleman Carol Aghajanian Gottfried E. Konecny David M. O’Malley Alexandra Leary Diane Provencher Stephen Welch Lee-may Chen Andrea E. Wahner Hendrickson Ling Ma Prafull Ghatage Rebecca S. Kristeleit Oliver Dorigo Ashan Musafer Scott H. Kaufmann Julia A. Elvin Douglas I. Lin Setsuko K. Chambers Erin Dominy Lan-Thanh Vo Sandra Goble Lara Maloney Heidi Giordano Thomas Harding Alexander Dobrovic Clare L. Scott Kevin K. Lin Iain A. McNeish
author_sort	Elizabeth M. Swisher
title	Molecular and clinical determinants of response and resistance to rucaparib for recurrent ovarian cancer treatment in ARIEL2 (Parts 1 and 2)
title_short	Molecular and clinical determinants of response and resistance to rucaparib for recurrent ovarian cancer treatment in ARIEL2 (Parts 1 and 2)
title_full	Molecular and clinical determinants of response and resistance to rucaparib for recurrent ovarian cancer treatment in ARIEL2 (Parts 1 and 2)
title_fullStr	Molecular and clinical determinants of response and resistance to rucaparib for recurrent ovarian cancer treatment in ARIEL2 (Parts 1 and 2)
title_full_unstemmed	Molecular and clinical determinants of response and resistance to rucaparib for recurrent ovarian cancer treatment in ARIEL2 (Parts 1 and 2)
title_sort	molecular and clinical determinants of response and resistance to rucaparib for recurrent ovarian cancer treatment in ariel2 (parts 1 and 2)
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/4c0bb318d2464bacb5fcd01f6ceefda3
work_keys_str_mv	AT elizabethmswisher molecularandclinicaldeterminantsofresponseandresistancetorucaparibforrecurrentovariancancertreatmentinariel2parts1and2 AT tanyatkwan molecularandclinicaldeterminantsofresponseandresistancetorucaparibforrecurrentovariancancertreatmentinariel2parts1and2 AT amitmoza molecularandclinicaldeterminantsofresponseandresistancetorucaparibforrecurrentovariancancertreatmentinariel2parts1and2 AT annavtinker molecularandclinicaldeterminantsofresponseandresistancetorucaparibforrecurrentovariancancertreatmentinariel2parts1and2 AT isabelleraycoquard molecularandclinicaldeterminantsofresponseandresistancetorucaparibforrecurrentovariancancertreatmentinariel2parts1and2 AT anaoaknin molecularandclinicaldeterminantsofresponseandresistancetorucaparibforrecurrentovariancancertreatmentinariel2parts1and2 AT robertlcoleman molecularandclinicaldeterminantsofresponseandresistancetorucaparibforrecurrentovariancancertreatmentinariel2parts1and2 AT carolaghajanian molecularandclinicaldeterminantsofresponseandresistancetorucaparibforrecurrentovariancancertreatmentinariel2parts1and2 AT gottfriedekonecny molecularandclinicaldeterminantsofresponseandresistancetorucaparibforrecurrentovariancancertreatmentinariel2parts1and2 AT davidmomalley molecularandclinicaldeterminantsofresponseandresistancetorucaparibforrecurrentovariancancertreatmentinariel2parts1and2 AT alexandraleary molecularandclinicaldeterminantsofresponseandresistancetorucaparibforrecurrentovariancancertreatmentinariel2parts1and2 AT dianeprovencher molecularandclinicaldeterminantsofresponseandresistancetorucaparibforrecurrentovariancancertreatmentinariel2parts1and2 AT stephenwelch molecularandclinicaldeterminantsofresponseandresistancetorucaparibforrecurrentovariancancertreatmentinariel2parts1and2 AT leemaychen molecularandclinicaldeterminantsofresponseandresistancetorucaparibforrecurrentovariancancertreatmentinariel2parts1and2 AT andreaewahnerhendrickson molecularandclinicaldeterminantsofresponseandresistancetorucaparibforrecurrentovariancancertreatmentinariel2parts1and2 AT lingma molecularandclinicaldeterminantsofresponseandresistancetorucaparibforrecurrentovariancancertreatmentinariel2parts1and2 AT prafullghatage molecularandclinicaldeterminantsofresponseandresistancetorucaparibforrecurrentovariancancertreatmentinariel2parts1and2 AT rebeccaskristeleit molecularandclinicaldeterminantsofresponseandresistancetorucaparibforrecurrentovariancancertreatmentinariel2parts1and2 AT oliverdorigo molecularandclinicaldeterminantsofresponseandresistancetorucaparibforrecurrentovariancancertreatmentinariel2parts1and2 AT ashanmusafer molecularandclinicaldeterminantsofresponseandresistancetorucaparibforrecurrentovariancancertreatmentinariel2parts1and2 AT scotthkaufmann molecularandclinicaldeterminantsofresponseandresistancetorucaparibforrecurrentovariancancertreatmentinariel2parts1and2 AT juliaaelvin molecularandclinicaldeterminantsofresponseandresistancetorucaparibforrecurrentovariancancertreatmentinariel2parts1and2 AT douglasilin molecularandclinicaldeterminantsofresponseandresistancetorucaparibforrecurrentovariancancertreatmentinariel2parts1and2 AT setsukokchambers molecularandclinicaldeterminantsofresponseandresistancetorucaparibforrecurrentovariancancertreatmentinariel2parts1and2 AT erindominy molecularandclinicaldeterminantsofresponseandresistancetorucaparibforrecurrentovariancancertreatmentinariel2parts1and2 AT lanthanhvo molecularandclinicaldeterminantsofresponseandresistancetorucaparibforrecurrentovariancancertreatmentinariel2parts1and2 AT sandragoble molecularandclinicaldeterminantsofresponseandresistancetorucaparibforrecurrentovariancancertreatmentinariel2parts1and2 AT laramaloney molecularandclinicaldeterminantsofresponseandresistancetorucaparibforrecurrentovariancancertreatmentinariel2parts1and2 AT heidigiordano molecularandclinicaldeterminantsofresponseandresistancetorucaparibforrecurrentovariancancertreatmentinariel2parts1and2 AT thomasharding molecularandclinicaldeterminantsofresponseandresistancetorucaparibforrecurrentovariancancertreatmentinariel2parts1and2 AT alexanderdobrovic molecularandclinicaldeterminantsofresponseandresistancetorucaparibforrecurrentovariancancertreatmentinariel2parts1and2 AT clarelscott molecularandclinicaldeterminantsofresponseandresistancetorucaparibforrecurrentovariancancertreatmentinariel2parts1and2 AT kevinklin molecularandclinicaldeterminantsofresponseandresistancetorucaparibforrecurrentovariancancertreatmentinariel2parts1and2 AT iainamcneish molecularandclinicaldeterminantsofresponseandresistancetorucaparibforrecurrentovariancancertreatmentinariel2parts1and2
_version_	1718391188039401472

Molecular and clinical determinants of response and resistance to rucaparib for recurrent ovarian cancer treatment in ARIEL2 (Parts 1 and 2)

Ejemplares similares